Advanced Search

Best antibiotics for buccal delivery

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Robert S. Langer, Jr. and Frederick H. Bowman. en_US Goldberg, Manijeh Nazari en_US
dc.contributor.other Harvard University--MIT Division of Health Sciences and Technology. en_US 2012-01-12T19:29:59Z 2012-01-12T19:29:59Z 2011 en_US 2011 en_US
dc.description Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2011. en_US
dc.description Cataloged from PDF version of thesis. en_US
dc.description Includes bibliographical references (p. 64-66). en_US
dc.description.abstract The purpose of the research was to identify the clinical and commercial benefits of switching from intravenous (IV) to buccal delivery of antibiotics. then, the research continued to select 3-5 antibiotics that best met the buccal delivery and market requirements. Methods: The research began with the hypothesis that some injectable antibiotics are good candidates for buccal delivery even with the limitations imposed by the buccal tissue. The thesis captures a two-year research period encompassing three critical fronts - the clinical viability of switching from IV to buccal delivery for antibiotics, the market's desire and readiness to switch, and the antibiotic brands available for commercialization. Then the research moved to drug identification and selection in order to assess the antibiotics that would best function in the buccal delivery model. Results: Intravenous (IV) antibiotics are usually reserved for severe infections that require faster treatment. Less aggressive bacterial growths are treated with oral antibiotics, which has fewer side effects and complications. In the past two decades, the understanding of drug transport across different tissues has increased resulting in improved patient adherence to the therapeutic regimen and pharmacologic response. The administration of drugs by transdermal or transmucosal routes are relatively painless, offers patients more choices, and reduces the need to establish intravenous access, which is a particular benefit for children and elderly. These alternative methods also provide clinical care providers with more choices to better manage their patient's course of treatment. In the past, clinicians administered sedatives, narcotics, and a variety of other medications by transdermal, sublingual, nasal, rectal, and even tracheal-mucosal routes. These delivery options have provided flexible practice settings and this paper intends to show that antibiotics could be the next set of drugs to be administered in variety of ways to provide patients and clinicians the best array of choices. Conclusion: A few years ago, the buccal delivery method was fairly unknown. However, advances in nano encapsulation, physiology, toxicity, and the availability of certain drugs make the timing ideal for introducing antibiotics that have undergone a highly selective process for delivering through the buccal tissue. en_US
dc.description.statementofresponsibility by Manijeh Nazari Goldberg. en_US
dc.format.extent 88 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri en_US
dc.subject Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.title Best antibiotics for buccal delivery en_US
dc.type Thesis en_US S.M. en_US
dc.contributor.department Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.identifier.oclc 769907148 en_US

Files in this item

Name Size Format Description
769907148-MIT.pdf 7.790Mb PDF Full printable version

This item appears in the following Collection(s)

Show simple item record